Skip to main content

Cleary Gottlieb Steen & Hamilton has served as legal counsel to Japan‘s Takeda Pharmaceutical on a $5.2 billion deal to acquire U.S.-based rare cancer drugmaker Ariad Pharmaceuticals, represented by Paul, Weiss, Rifkind, Wharton & Garrison.

The transaction is expected to close by the end of February 2017. With this deal, Takeda gains access to Iclusig, Ariad’s leukemia drug, which is estimated to generate sales of $170 million-$180 million in 2016, according to Reuters.

Cancer drugs are attractive to pharma giants, which pay high prices promising assets, reported Reuters. In September, Takeda announced it was seeking multi-billion dollar acquisitions to cut back its dependence on domestic sales.

Velcade, Takeda's blockbuster blood cancer medicine, is expected to face market competition from generic drugmakers this year. In addition, other key Takeda products will go off patent from 2020.

Takeda said it will finance the acquisition by taking on $4 billion in new debt.

 

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.